{"id":50960,"date":"2025-12-16T21:42:26","date_gmt":"2025-12-16T13:42:26","guid":{"rendered":"https:\/\/flcube.com\/?p=50960"},"modified":"2025-12-16T21:42:28","modified_gmt":"2025-12-16T13:42:28","slug":"adaptive-licenses-tcr-data-to-pfizer-in-890m-deal-for-rheumatoid-arthritis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50960","title":{"rendered":"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis"},"content":{"rendered":"\n<p><strong>Adaptive Biotechnologies Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ADPT:NASDAQ\">NASDAQ: ADPT<\/a>) announced two non\u2011exclusive agreements with <strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) to leverage its proprietary <strong>T\u2011cell receptor (TCR) discovery capabilities<\/strong> and large\u2011scale immune receptor antigen mapping data. Pfizer will use Adaptive\u2019s platform to identify RA\u2011causing TCRs as therapeutic targets and license TCR\u2011antigen data to train its AI\/ML models.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Agreement<\/th><th>Scope<\/th><th>Financial Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>TCR Discovery for RA<\/strong><\/td><td>Adaptive to identify disease\u2011causing TCRs from Pfizer\u2019s clinical samples<\/td><td>Upfront payment + milestones<\/td><\/tr><tr><td><strong>Data Licensing for AI\/ML<\/strong><\/td><td>Pfizer licenses TCR\u2011antigen data to accelerate drug discovery<\/td><td>Included in overall deal structure<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>Up to <strong>USD 890 million<\/strong> (development, commercial, sales milestones)<\/td><td>Excludes royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-application\">Technology Application<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Platform<\/th><th>Use Case<\/th><\/tr><\/thead><tbody><tr><td><strong>Adaptive\u2019s Immune Medicine Platform<\/strong><\/td><td>Identifies TCRs significantly enriched in rheumatoid arthritis patients<\/td><\/tr><tr><td><strong>Large\u2011Scale Immune Receptor Mapping<\/strong><\/td><td>Provides antigen\u2011specific data for AI\/ML model training<\/td><\/tr><tr><td><strong>Pfizer\u2019s Application<\/strong><\/td><td>Accelerates RA therapeutic candidate development; enhances AI drug discovery across multiple diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Adaptive:<\/strong> <strong>$890 million potential<\/strong> monetizes TCR database beyond oncology; validates platform in <strong>autoimmune disease<\/strong>; creates recurring revenue model via data licensing.<\/li>\n\n\n\n<li><strong>For Pfizer:<\/strong> Access to <strong>clinically validated TCR targets<\/strong> de\u2011risks RA pipeline; AI\/ML data enhances <strong>computational drug discovery<\/strong> capabilities; complements existing inflammation franchise (Xeljanz, Enbrel).<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Demonstrates growing value of <strong>immune repertoire data<\/strong> in drug discovery; positions TCR platforms as strategic assets for pharma AI initiatives.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, platform utilization, and market opportunities. Actual results may differ due to scientific risks, competitive dynamics, or clinical outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non\u2011exclusive agreements with Pfizer Inc. (NYSE: PFE) to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50961,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4293,99,4506,863,309],"class_list":["post-50960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adaptive-biotechnologies","tag-ai","tag-nasdaq-adpt","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non\u2011exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage its proprietary T\u2011cell receptor (TCR) discovery capabilities and large\u2011scale immune receptor antigen mapping data. Pfizer will use Adaptive\u2019s platform to identify RA\u2011causing TCRs as therapeutic targets and license TCR\u2011antigen data to train its AI\/ML models.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50960\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis\" \/>\n<meta property=\"og:description\" content=\"Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non\u2011exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage its proprietary T\u2011cell receptor (TCR) discovery capabilities and large\u2011scale immune receptor antigen mapping data. Pfizer will use Adaptive\u2019s platform to identify RA\u2011causing TCRs as therapeutic targets and license TCR\u2011antigen data to train its AI\/ML models.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50960\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-16T13:42:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-16T13:42:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis\",\"datePublished\":\"2025-12-16T13:42:26+00:00\",\"dateModified\":\"2025-12-16T13:42:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1601.webp\",\"keywords\":[\"Adaptive Biotechnologies\",\"AI\",\"NASDAQ: ADPT\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50960#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50960\",\"name\":\"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1601.webp\",\"datePublished\":\"2025-12-16T13:42:26+00:00\",\"dateModified\":\"2025-12-16T13:42:28+00:00\",\"description\":\"Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non\u2011exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage its proprietary T\u2011cell receptor (TCR) discovery capabilities and large\u2011scale immune receptor antigen mapping data. Pfizer will use Adaptive\u2019s platform to identify RA\u2011causing TCRs as therapeutic targets and license TCR\u2011antigen data to train its AI\\\/ML models.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50960\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50960#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis - Insight, China&#039;s Pharmaceutical Industry","description":"Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non\u2011exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage its proprietary T\u2011cell receptor (TCR) discovery capabilities and large\u2011scale immune receptor antigen mapping data. Pfizer will use Adaptive\u2019s platform to identify RA\u2011causing TCRs as therapeutic targets and license TCR\u2011antigen data to train its AI\/ML models.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50960","og_locale":"en_US","og_type":"article","og_title":"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis","og_description":"Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non\u2011exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage its proprietary T\u2011cell receptor (TCR) discovery capabilities and large\u2011scale immune receptor antigen mapping data. Pfizer will use Adaptive\u2019s platform to identify RA\u2011causing TCRs as therapeutic targets and license TCR\u2011antigen data to train its AI\/ML models.","og_url":"https:\/\/flcube.com\/?p=50960","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-16T13:42:26+00:00","article_modified_time":"2025-12-16T13:42:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50960#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50960"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis","datePublished":"2025-12-16T13:42:26+00:00","dateModified":"2025-12-16T13:42:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50960"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50960#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1601.webp","keywords":["Adaptive Biotechnologies","AI","NASDAQ: ADPT","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50960#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50960","url":"https:\/\/flcube.com\/?p=50960","name":"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50960#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50960#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1601.webp","datePublished":"2025-12-16T13:42:26+00:00","dateModified":"2025-12-16T13:42:28+00:00","description":"Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non\u2011exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage its proprietary T\u2011cell receptor (TCR) discovery capabilities and large\u2011scale immune receptor antigen mapping data. Pfizer will use Adaptive\u2019s platform to identify RA\u2011causing TCRs as therapeutic targets and license TCR\u2011antigen data to train its AI\/ML models.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50960#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50960"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50960#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1601.webp","width":1080,"height":608,"caption":"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50960#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50960"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50960\/revisions"}],"predecessor-version":[{"id":50967,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50960\/revisions\/50967"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50961"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}